The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Open accessAbstract
Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions. To date, nab-paclitaxel has been indicated for the treatment of three solid tumors in the USA. It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013. Nab-paclitaxel is also under investigation for the treatment of a number of other solid tumors. This review highlights key clinical efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel's indications into other solid tumors, and provides a clinical perspective on the use of nab-paclitaxel in practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 595
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Langer, C. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.173 · Cited by 502
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 444
Ueno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605256 · Cited by 439
Frese, K. K., Neesse, A., Cook, N., Bapiro, T. E., Lolkema, M. P., Jodrell, D. I., & Tuveson, D. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0242 · Cited by 415
Desai, N., Trieu, V., Damascelli, B., & Soon-Shiong, P. (2009) · Translational Oncology · doi:10.1593/tlo.09109 · Cited by 396
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1144 · Cited by 348
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5397 · Cited by 341
(1999) · PubMed · Cited by 337
Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286
Abou-Alfa, G. K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N. S., Feit, K., Ackerman, J., De Jager, R. L., Eckhardt, S. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0201 · Cited by 282
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02770 · Cited by 270
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Luvero, D., Milani, A., & Ledermann, J. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014544121 · Cited by 260
Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., Toppmeyer, D., Carey, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5298 · Cited by 222
Physiologic Aspects of Aging: Impact on Cancer Management and Decision Making, Part I
Sawhney, R., Sehl, M., & Naeim, A. (2005) · The Cancer Journal · doi:10.1097/00130404-200511000-00004 · Cited by 214
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
Tellingen, O. V., Huizing, M. T., Panday, V. R. N., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690696 · Cited by 211
Cetin, K., Ettinger, D. S., Hei, & O'Malley, C. (2011) · Clinical Epidemiology · doi:10.2147/clep.s17191 · Cited by 198
Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
(2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0035 · Cited by 181
Review on Pharmacokinetics and Pharmacodynamics and the Aging Kidney
Aymanns, C., Keller, F., Maus, S., Hartmann, B., & Czock, D. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03960609 · Cited by 159
Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L., & Palmieri, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn661 · Cited by 145
Physiologic Aspects of Aging: Impact on Cancer Management and Decision Making, Part II
Sehl, M. E., Sawhney, R., & Naeim, A. (2005) · The Cancer Journal · doi:10.1097/00130404-200511000-00005 · Cited by 127
Chen, N., Li, Y., Ye, Y., Palmisano, M., Chopra, R., & Zhou, S. Y. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.304 · Cited by 123
Coleman, R. L., Brady, W. E., McMeekin, D. S., Rose, P. G., Soper, J. T., Lentz, S. S., Hoffman, J. S., & Shahin, M. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.036 · Cited by 122
Hersh, E. M., O'Day, S. J., Ribas, A., Samlowski, W. E., Gordon, M. S., Shechter, D. E., Clawson, A., & Gonzalez, R. C. (2009) · Cancer · doi:10.1002/cncr.24720 · Cited by 119
Gradishar, W. J., Krasnojon, D., Валентинович, Ч. С., Makhson, A. N., Manikhas, G., Clawson, A., Bhar, P., McGuire, J. R., & Iglesias, J. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.05.001 · Cited by 119
Hofmann, D., Nitz, U. A., Gluz, O., et al. (2013) · Trials · doi:10.1186/1745-6215-14-261 · Cited by 115
Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H., & Renschler, M. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mds461 · Cited by 108
Hersh, E. M., Vecchio, M. D., Brown, M. P., Kefford, R. F., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R. M., Haydon, A. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv324 · Cited by 102
Kottschade, L. A., Suman, V. J., AMATRUDA, T. T., McWilliams, R. R., Mattar, B. I., Nikcevich, D. A., Behrens, R. J., Fitch, T. R., Jaslowski, A. J., & Markovic, S. N. (2010) · Cancer · doi:10.1002/cncr.25659 · Cited by 98
Lobo, C. F., Lopes, G. D. L., Jr., Baez, O., Castrellon, A. B., Ferrell, A., Higgins, C., Hurley, E., Hurley, J. E., dos Reis, I. M., Richman, S. P., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1002-0 · Cited by 90
Teneriello, M. G., Tseng, P. C., Crozier, M., Encarnacion, C. A., Hancock, K. C., Messing, M. J., Boehm, K. A., Williams, A., & Asmar, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9548 · Cited by 80
Socinski, M. A., Manikhas, G., Stroyakovskiy, D., Makhson, A. N., Валентинович, Ч. С., Орлов, С. В., Yablonsky, P. K., Bhar, P., & Iglesias, J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d5e39e · Cited by 78
Tsao, A. S. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.07.002 · Cited by 75
Socinski, M. A., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J. M., Yamamoto, N., Zhang, H., & Renschler, M. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt235 · Cited by 70
Hamilton, E. P., Kimmick, G. G., Hopkins, J. O., Marcom, P. K., Rocha, G., Welch, R. A., Broadwater, G., & Blackwell, K. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.003 · Cited by 62
Rugo, H. S., Barry, W. T., Moreno‐Aspitia, A., Lyss, A. P., Cirrincione, C., Mayer, E. L., Naughton, M., Layman, R. M., Carey, L., Somer, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.cra1002 · Cited by 62
Blanchard, E. M., Moon, J., Hesketh, P. J., Kelly, K. L., Wozniak, A. J., Crowley, J. J., & Gandara, D. R. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fbebfd · Cited by 51
Li, Y., Chen, N., Palmisano, M., & Zhou, S. Y. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00026 · Cited by 47
Hirsh, V., Okamoto, I., Hon, J. K., Page, R. D., Orsini, J. M., Sakai, H., Zhang, H., Renschler, M. F., & Socinski, M. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000011 · Cited by 33
Cited by
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Precise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 409
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 274
Metadata
- Authors
- Kundranda, M., & Niu, J.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-07
- Volume
- 9
- Pages
- 3767
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1927137508
- Cited by
- 255
- References
- 61
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.